Dr. Isaacs Discusses Antibody Drug Conjugates in TNBC

Video

In Partnership With:

Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses antibody drug conjugates in the treatment of patients with triple-negative breast cancer.

Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses antibody drug conjugates (ADCs) in the treatment of patients with triple-negative breast cancer (TNBC).

Isaacs predicts that a breakthrough is imminent in the treatment of TNBC, with positive data from phase II trials now being studied in phase III trials. ADCs target an antigen that is present in a fair proportion of patients with TNBC, and results are indicating benefit in heavily pre-treated patients with metastatic disease.

The ADC sacituzumab govitecan (IMMU-132) targets TROP-2, which is an antigen present in a significant proportion of patients with TNBC. In a recent study of 110 patients, treatment with sacituzumab govitecan elicited an objective response rate of 34% in patients with heavily pretreated metastatic TNBC.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center